E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10022002 |
E.1.2 | Term | Influenza A virus infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to determine the effect of oral administration of VX 787 administered post-inoculation on the AUC of viral titers quantified by nasal swab cell culture in a human challenge model of influenza. |
|
E.2.2 | Secondary objectives of the trial |
- Safety and tolerability of VX 787 in healthy adult subjects inoculated with live influenza virus
- Safety of the GMP manufactured influenza virus inoculum strain in susceptible, healthy subjects receiving either VX 787 or placebo
- Influenza viral kinetics from nasal swabs by RT PCR
- Change and severity of clinical symptoms
- Changes in the sequence of the relevant target region of influenza in nasal swabs
- Pharmacokinetics of VX 787 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Healthy male and female subjects
- Negative human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) antibody screen
- Negative Class A drugs and alcohol screen before dosing
- Serosuitable for the challenge strain of influenza A
- Have not been vaccinated for influenza virus since 2006 or had a known influenza-like illness in the current season (as determined in the medical history), defined as in the last 12 months before screening
- Willing and able to comply with all scheduled visits, treatment plan, clinical laboratory tests, lifestyle guidelines, contraceptive guidelines, and other study procedures, including willingness to enter and remain in quarantine (in isolation for approximately 10 days) until free of influenza infection, as determined by rapid antigen test or clinical evaluation |
|
E.4 | Principal exclusion criteria |
- Subjects who are male and their female partner (if of childbearing potential) does not agree to use medically approved methods of contraception
- Subjects who are pregnant or nursing, or who are male and have a female partner who is pregnant, nursing, or is planning to become pregnant during the study period
- Presence of any significant acute or chronic, uncontrolled medical or psychiatric illness
- Abnormal pulmonary function as evidenced by clinically significant abnormalities in spirometry
- Health care workers (including doctors, nurses, medical students and allied healthcare professionals) anticipated to have patient contact within two weeks of viral challenge)
- Subjects with a history of asthma, COPD, pulmonary hypertension, reactive airway disease, or any chronic lung condition of any etiology; any history during adulthood of asthma of any etiology, chronic obstructive pulmonary disease, or any use of a bronchodilator or other asthma medication during adulthood
-Regular daily smokers during the 6 months before study entry or those who have a significant history of any tobacco use at any time
- History of heart failure or any other severe cardiac abnormality including clinically significant arrhythmia
- Use of any prescription drugs, herbal supplements, within 4 weeks before drug IMP administration, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within 2 weeks before viral challenge.
- Receipt of any investigational drug within 3 months, or prior participation in a clinical trial of any influenza vaccine, medication or experimental respiratory viral challenge delivered directly to the respiratory tract within 1 year before viral inoculation
- Previous exposure to the IMP or similar substance(s).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is Viral AUC as calculated in cell culture of nasal swabs (quantitation of nasal swabs for viral infectivity by cell culture), from initiation of VX 787 treatment. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Safety and tolerability based on assessment of adverse events, clinical laboratory assessments, 12-lead electrocardiograms (ECGs), and vital signs
- Viral kinetics in relation to:
o Viral AUC calculated by cell culture and/or RT-PCR
o Duration of viral shedding by cell culture and/or RT-PCR
o Peak viral shedding titre by cell culture and/or RT-PCR
o Time to resolution from peak viral shedding by cell culture and/or RT-PCR
- Clinical symptom scores
o Composite symptom score AUC
o Time to peak of composite symptom score, duration, and time to resolution of composite score from peak
o Peak severity symptoms after influenza viral inoculation
o Duration of influenza-like illness after influenza viral inoculation
- Total tissue count and total mucus weight post challenge
- Sequence analysis of the relevant target region of influenza
- Pharmacokinetic parameters of VX 787 (AUC, Cmax, Cmin, tmax)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 6 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 0 |